- ¥231bn
- ¥159bn
- ¥171bn
Table: Nippon Shinyaku -Q1 group results (IFRS)
Table: Nippon Shinyaku -2023/24 group results (IFRS)
Brief: Mina Therapeutics Enters Collaboration With Nippon Shinyaku
Brief: Vicore And Nippon Shinyaku Enter Into An Exclusive License Agreement
Table: Nippon Shinyaku -9-MTH group results (IFRS)
Brief: Ns Pharma, European Commission Granted Orphan Drug Designation To Ns-229 For Treatment Of Eosinophilic Granulomatosis With Polyangiitis
Table: Nippon Shinyaku -2023/24 group forecast(IFRS)
Table: Nippon Shinyaku -2023/24 div forecast
Table: Nippon Shinyaku -6-MTH group results (IFRS)
2023 6-month group forecast(IFRS)
Table: Nippon Shinyaku -Q1 group results (IFRS)
Brief: FDA Grants Breakthrough Therapy Designation To NS-089/NCNP-02 For The Treatment Of Duchenne Muscular Dystrophy
Brief: NS Pharma FDA Granted Rare Pediatric Disease Designation To NS-089/NCNP-02 For Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping Therapy
Table: Nippon Shinyaku -2022/23 group results (IFRS)
Brief: Ns Pharma Announces FDA Clearance To Initiate Phase Ii Study For Ns-089/Ncnp-02, An Exon 44 Skipping Candidate For Treatment Of Duchenne Muscular Dystrophy
Brief: Capricor Therapeutics And Nippon Shinyaku Enter Partnership For Exclusive Commercialization And Distribution Of Cap-1002 For The Treatment Of Duchenne Muscular Dystrophy In Japan
Table: Nippon Shinyaku -9-MTH group results (IFRS)
Table: Nippon Shinyaku -2022/23 div forecast
Table: Nippon Shinyaku -6-MTH group results (IFRS)